Sophia Clune

MedicineBiochemistry, Genetics and Molecular BiologyImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “The validation of new CHD1L inhibitors as a therapeutic strategy for cancer”.

The validation of new CHD1L inhibitors as a therapeutic strategy for cancer

Biomedicine & Pharmacotherapy(2023)10.1016/j.biopha.2023.116037

N/A

0.330DataRank · unranked

8 citations

Paul Awolade, Qiong Zhou, Hector Esquer, Brock Matter, J. Kearns +5 more

CHD1L Inhibitor OTI-611 Synergizes with Chemotherapy to Enhance Antitumor Efficacy and Prolong Survival in Colorectal Cancer Mouse Models

International Journal of Molecular Sciences(2024)10.3390/ijms252313160

N/A

0DataRank · unranked

5 citations

Hector Esquer, Timothy Kellett, Sophia Clune, Paul Awolade, Laura A. Pike +4 more

CHD1L in cancer and beyond: structure, oncogenic functions, and therapeutic potential

Journal of Experimental & Clinical Cancer Research(2025)10.1186/s13046-025-03428-1

N/A

0DataRank · unranked

2 citations

Paul Awolade, Hector Esquer, Qiong Zhou, Daniel V. LaBarbera, Sophia Clune